Literature DB >> 18227512

Sublingual vaccination with influenza virus protects mice against lethal viral infection.

Joo-Hye Song1, Huan H Nguyen, Nicolas Cuburu, Taisuke Horimoto, Sung-Youl Ko, Se-Ho Park, Cecil Czerkinsky, Mi-Na Kweon.   

Abstract

We assessed whether the sublingual (s.l.) route would be an effective means of delivering vaccines against influenza virus in mice by using either formalin-inactivated or live influenza A/PR/8 virus (H1N1). Sublingual administration of inactivated influenza virus given on two occasions induced both systemic and mucosal antibody responses and conferred protection against a lethal intranasal (i.n.) challenge with influenza virus. Coadministration of a mucosal adjuvant (mCTA-LTB) enhanced these responses and resulted in complete protection against respiratory viral challenge. In addition, s.l. administration of formalin-inactivated A/PR/8 plus mCTA-LTB induced systemic expansion of IFN-gamma-secreting T cells and virus-specific cytotoxic T lymphocyte responses. Importantly, a single s.l. administration of live A/PR/8 virus was not pathogenic and induced protection mediated by both acquired and innate immunity. Moreover, s.l. administration of live A/PR/8 virus conferred heterosubtypic protection against respiratory challenge with H3N2 virus. Unlike the i.n. route, the A/PR/8 virus, whether live or inactivated, did not migrate to or replicate in the CNS after s.l. administration. Based on these promising findings, we propose that the s.l. mucosal route offers an attractive alternative to mucosal routes for administering influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227512      PMCID: PMC2234198          DOI: 10.1073/pnas.0708684105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

Review 1.  Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease.

Authors:  Janine Bilsborough; Joanne L Viney
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

2.  Safety of sublingual immunotherapy with a monomeric allergoid in very young children.

Authors:  F Agostinis; L Tellarini; G W Canonica; P Falagiani; G Passalacqua
Journal:  Allergy       Date:  2005-01       Impact factor: 13.146

3.  Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women.

Authors:  P A Kozlowski; S Cu-Uvin; M R Neutra; T P Flanigan
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

Review 4.  Immunoglobulin A: strategic defense initiative at the mucosal surface.

Authors:  B J Underdown; J M Schiff
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

Authors:  C C Czerkinsky; L A Nilsson; H Nygren; O Ouchterlony; A Tarkowski
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus.

Authors:  Loïc Guillot; Ronan Le Goffic; Sarah Bloch; Nicolas Escriou; Shizuo Akira; Michel Chignard; Mustapha Si-Tahar
Journal:  J Biol Chem       Date:  2004-12-03       Impact factor: 5.157

7.  Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.

Authors:  Sandra S Diebold; Tsuneyasu Kaisho; Hiroaki Hemmi; Shizuo Akira; Caetano Reis e Sousa
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

8.  Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.

Authors:  M L Clements; S O'Donnell; M M Levine; R M Chanock; B R Murphy
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

9.  Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.

Authors:  F Y Liew; S M Russell; G Appleyard; C M Brand; J Beale
Journal:  Eur J Immunol       Date:  1984-04       Impact factor: 5.532

Review 10.  NALT- versus Peyer's-patch-mediated mucosal immunity.

Authors:  Hiroshi Kiyono; Satoshi Fukuyama
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

View more
  71 in total

1.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

2.  Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.

Authors:  Celine A Hayden; Stephen J Streatfield; Barry J Lamphear; Gina M Fake; Todd K Keener; John H Walker; John D Clements; Debra D Turner; Ian R Tizard; John A Howard
Journal:  Vaccine       Date:  2012-03-08       Impact factor: 3.641

3.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

4.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

Review 5.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

Review 6.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.

Authors:  Byoung-Shik Shim; Jung-Ah Choi; Ho-Hyun Song; Sung-Moo Park; In Su Cheon; Ji-Eun Jang; Sun Je Woo; Chung Hwan Cho; Min-Suk Song; Hyemi Kim; Kyung Joo Song; Jae Myun Lee; Suhng Wook Kim; Dae Sub Song; Young Ki Choi; Jae-Ouk Kim; Huan Huu Nguyen; Dong Wook Kim; Young Yil Bahk; Cheol-Heui Yun; Man Ki Song
Journal:  J Microbiol       Date:  2013-03-02       Impact factor: 3.422

9.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

10.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.